Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

World COPD Day

  • Home Blog Chronic obstructive pulmonary disease treatment

World COPD Day

Nov 20, 2019

World COPD day observed on every 3rd Wednesday of November. This year, on 20th November, we are creating awareness about Chronic Obstructive Pulmonary Disease.

COPD is one of the leading causes of mortality and morbidity worldwide. COPD is of two types: Emphysema and Chronic Bronchitis.

According to a report by the National Health Interview Survey, the estimated prevalence of emphysema is found to be 18 cases per 1000 persons and for chronic bronchitis, 34 cases per 1000 persons.

Downloads

Article in PDF

Recent Articles
  1. AstraZeneca’s new Asthma Drug Aces Phase III trial
  2. PTC Therapeutics’ Gene Therapy Upstaza; Sanofi and Regeneron’s Dupixent; Bayer CAR-T Collaboratio...
  3. Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipo...
  4. ATS 2023 Updates: Dupixent – A Ray of Hope For Moderate To Severe Chronic Obstructive Pulmo...
  5. IntraBio’s AQNEURSA Niemann-Pick Disease Approval; FDA Approves Novel Schizophrenia Drug After 35...
Pharma-news-for-bms-intrabio-pfizer
Notizia - Recent Pharma, Healthcare and Biotech Happenings

IntraBio’s AQNEURSA Niemann-Pick Disease Approval; FDA Approves Novel Schizophrenia Drug After 35 Years; Selpercatinib Gets FDA Nod for RET-Mutated MTC; DUPIXENT Receives First-Ever COPD Approval; Pfizer Withdraws OXBRYTA for Sickle Cell Disease from Global Market

Pharma-news-for-biogen-travere-GSK
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Biogen’s SPINRAZA Phase II/III Trial Results; Travere’s FILSPARI FDA Approval; GSK’s NUCALA Succeeds in COPD Trial; Summit’s NSCLC Win Over KEYTRUDA Raises Caution; FDA Lifts Hold on RZ358 for Congenital Hyperinsulinism

pharma-news-for-eli-lilly-ideaya-roche-sanofi
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Lilly’s Morphic Acquisition; IDEAYA’s IDE397 Positive Phase II Trial Result; XPOVIO (selinexor) Approval in China; Roche to Reintroduce Susvimo in the US; Dupixent EU Approval

Chronic Obstructive Pulmonary Disease
lung disease
loader